Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Cancer Invest. 2011 Aug;29(7):485-93. doi: 10.3109/07357907.2011.597812.
Tumor necrosis factor (TNF)-α has been proved as an adjuvant therapy for tumor by FDA. However, the effect of chronic TNF-α expression for tumor is still controversial. In this study, we investigated the effect of low-dose TNF-α on tumor growth. We confirmed that low-dose TNF-α promoted angiogenesis of tumor in vivo, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α, the transcription factor of VEGF, were both upregulated. Our results suggested that low-dose TNF-α was a powerful activator of angiogenesis in tumor and HIF-1α-VEGF pathway seemed to be the most important molecular mechanism.
肿瘤坏死因子 (TNF)-α 已被 FDA 证实为肿瘤的辅助治疗药物。然而，慢性 TNF-α 表达对肿瘤的影响仍存在争议。在本研究中，我们研究了低剂量 TNF-α 对肿瘤生长的影响。我们证实低剂量 TNF-α促进了体内肿瘤的血管生成，血管内皮生长因子 (VEGF) 和缺氧诱导因子 (HIF)-1α，即 VEGF 的转录因子，均上调。我们的结果表明，低剂量 TNF-α是肿瘤血管生成的有力激活剂，HIF-1α-VEGF 途径似乎是最重要的分子机制。
